BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 37815464)

  • 1. Altered binding affinity of SIX1-Q177R correlates with enhanced WNT5A and WNT pathway effector expression in Wilms tumor.
    Stevenson MJ; Phanor SK; Patel U; Gisselbrecht SS; Bulyk ML; O'Brien LL
    Dis Model Mech; 2023 Nov; 16(11):. PubMed ID: 37815464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Iroquois homeobox proteins IRX3 and IRX5 have distinct roles in Wilms tumour development and human nephrogenesis.
    Holmquist Mengelbier L; Lindell-Munther S; Yasui H; Jansson C; Esfandyari J; Karlsson J; Lau K; Hui CC; Bexell D; Hopyan S; Gisselsson D
    J Pathol; 2019 Jan; 247(1):86-98. PubMed ID: 30246301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors.
    Wegert J; Ishaque N; Vardapour R; Geörg C; Gu Z; Bieg M; Ziegler B; Bausenwein S; Nourkami N; Ludwig N; Keller A; Grimm C; Kneitz S; Williams RD; Chagtai T; Pritchard-Jones K; van Sluis P; Volckmann R; Koster J; Versteeg R; Acha T; O'Sullivan MJ; Bode PK; Niggli F; Tytgat GA; van Tinteren H; van den Heuvel-Eibrink MM; Meese E; Vokuhl C; Leuschner I; Graf N; Eils R; Pfister SM; Kool M; Gessler M
    Cancer Cell; 2015 Feb; 27(2):298-311. PubMed ID: 25670083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIX1 protein expression selectively identifies blastemal elements in Wilms tumor.
    Sehic D; Karlsson J; Sandstedt B; Gisselsson D
    Pediatr Blood Cancer; 2012 Jul; 59(1):62-8. PubMed ID: 22180226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of CITED1, SIX1, and CD56 protein expression for identification of blastemal elements in Wilms tumor.
    Sehic D; Ciornei CD; Gisselsson D
    Am J Clin Pathol; 2014 Jun; 141(6):828-33. PubMed ID: 24838327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WNT5A is regulated by PAX2 and may be involved in blastemal predominant Wilms tumorigenesis.
    Tamimi Y; Ekuere U; Laughton N; Grundy P
    Neoplasia; 2008 Dec; 10(12):1470-80. PubMed ID: 19048125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors.
    Walz AL; Ooms A; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Bowlby R; Brooks D; Ma Y; Mungall AJ; Moore RA; Schein J; Marra MA; Huff V; Dome JS; Chi YY; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Jafari N; Ross N; Gastier-Foster JM; Perlman EJ
    Cancer Cell; 2015 Feb; 27(2):286-97. PubMed ID: 25670082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.
    Spreafico F; Ciceri S; Gamba B; Torri F; Terenziani M; Collini P; Macciardi F; Radice P; Perotti D
    Oncotarget; 2016 Feb; 7(8):8908-15. PubMed ID: 26802027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential regulation of mouse and human nephron progenitors by the Six family of transcriptional regulators.
    O'Brien LL; Guo Q; Lee Y; Tran T; Benazet JD; Whitney PH; Valouev A; McMahon AP
    Development; 2016 Feb; 143(4):595-608. PubMed ID: 26884396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
    Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
    Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study.
    Gadd S; Huff V; Skol AD; Renfro LA; Fernandez CV; Mullen EA; Jones CD; Hoadley KA; Yap KL; Ramirez NC; Aris S; Phung QH; Perlman EJ
    Cell Rep Med; 2022 Jun; 3(6):100644. PubMed ID: 35617957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.
    Natrajan R; Little SE; Reis-Filho JS; Hing L; Messahel B; Grundy PE; Dome JS; Schneider T; Vujanic GM; Pritchard-Jones K; Jones C
    Clin Cancer Res; 2006 Dec; 12(24):7284-93. PubMed ID: 17189400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the mutational status of SIX1/2 and microRNA processing genes in paired primary and relapsed Wilms tumors and association with relapse.
    Ciceri S; Montalvão-de-Azevedo R; Tajbakhsh A; Bertolotti A; Spagnuolo RD; Boschetti L; Capasso M; D'Angelo P; Serra A; Diomedi-Camassei F; Meli M; Nantron M; Quarello P; Buccoliero AM; Tamburini A; Ciniselli CM; Verderio P; Collini P; Radice P; Spreafico F; Perotti D
    Cancer Gene Ther; 2021 Sep; 28(9):1016-1024. PubMed ID: 33281191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse.
    Natrajan R; Reis-Filho JS; Little SE; Messahel B; Brundler MA; Dome JS; Grundy PE; Vujanic GM; Pritchard-Jones K; Jones C
    Cancer Res; 2006 Dec; 66(23):11148-55. PubMed ID: 17145858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA expression of the WT1 gene in Wilms' tumors in relation to histology.
    Miwa H; Tomlinson GE; Timmons CF; Huff V; Cohn SL; Strong LC; Saunders GF
    J Natl Cancer Inst; 1992 Feb; 84(3):181-7. PubMed ID: 1311774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal blastemal cell gene expression analysis in the kidney reveals new Wnt and related signaling pathway genes to be essential for Wilms' tumor onset.
    Maschietto M; Trapé AP; Piccoli FS; Ricca TI; Dias AA; Coudry RA; Galante PA; Torres C; Fahhan L; Lourenço S; Grundy PE; de Camargo B; de Souza S; Neves EJ; Soares FA; Brentani H; Carraro DM
    Cell Death Dis; 2011 Nov; 2(11):e224. PubMed ID: 22048167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors.
    Koesters R; Ridder R; Kopp-Schneider A; Betts D; Adams V; Niggli F; Briner J; von Knebel Doeberitz M
    Cancer Res; 1999 Aug; 59(16):3880-2. PubMed ID: 10463574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of TCF3 as potential master regulator in blastemal Wilms tumors.
    Kehl T; Schneider L; Kattler K; Stöckel D; Wegert J; Gerstner N; Ludwig N; Distler U; Tenzer S; Gessler M; Walter J; Keller A; Graf N; Meese E; Lenhof HP
    Int J Cancer; 2019 Mar; 144(6):1432-1443. PubMed ID: 30155889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition.
    Li CM; Guo M; Borczuk A; Powell CA; Wei M; Thaker HM; Friedman R; Klein U; Tycko B
    Am J Pathol; 2002 Jun; 160(6):2181-90. PubMed ID: 12057921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
    Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
    J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.